April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
In vivo Effects of 2-AEMP Analog of GABA, a GABAc Receptor Antagonist, on Dark-Adapted Mouse ERG
Author Affiliations & Notes
  • J. Wang
    College of Optometry, University of Houston, Houston, Texas
  • A. Xie
    Dept. of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • J. Yan
    Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee
  • R. F. Standaert
    Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee
  • H. Qian
    Dept. of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • D. R. Pepperberg
    Dept. of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • L. J. Frishman
    College of Optometry, University of Houston, Houston, Texas
  • Footnotes
    Commercial Relationships  J. Wang, None; A. Xie, None; J. Yan, None; R.F. Standaert, None; H. Qian, None; D.R. Pepperberg, None; L.J. Frishman, None.
  • Footnotes
    Support  NIH EY06671, EY07551, EY016094, EY001792. Daniel F. and Ada L. Rice Foundation, Hope for Vision, American Health Assistance Foundation, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2179. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Wang, A. Xie, J. Yan, R. F. Standaert, H. Qian, D. R. Pepperberg, L. J. Frishman; In vivo Effects of 2-AEMP Analog of GABA, a GABAc Receptor Antagonist, on Dark-Adapted Mouse ERG. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2179. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare effects of 2-aminoethyl methylphosphonate (2-AEMP) analogue of GABA, recently reported to have GABAc antagonist properties in vitro in Xenopus oocytes (Chowdhury et al., 2007), with effects of a known GABAc receptor antagonist, 1, 2, 5, 6-tetrahydropyridine -4-yl-methylphosphinic acid (TPMPA), in vivo.

Methods: : Dark-adapted ganzfeld ERGs were recorded from anesthetized C57BL/6 mice before and after intravitreal injection of TPMPA (50 µM vitreal conc. (vc), n=4) and 2-AEMP (1 mM vc, n=5), in response to brief flashes (-6.0 to 3.1 log sc td s). After oscillatory potentials (OPs > 50 Hz) were removed, ERG amplitudes were measured at the peak of the scotopic b-wave,110 ms after flash onset, and between a-wave trough and b-wave peak. For OP amplitude, the area under the OP power spectral density curve, i.e. total power, was calculated. Recordings (whole-cell voltage clamp) also were made from bipolar cells enzymatically isolated from rat retina.

Results: : Injection of TPMPA attenuated b-wave amplitudes, commencing at -2.6 log sc td s, and increasing up to b-wave saturation (-0.9 log sc td s), and then remaining at 49±8% reduction for measurements at 110 ms, and similarly by 45±6% for trough to peak amplitudes. Injection of 2-AEMP slightly attenuated b-wave amplitudes around -3.2 log sc td s, and the attenuation increased up to b-wave saturation (-0.9 log sc td s) with 31±9% reduction at 110 ms, and 25±9% for peak to trough. Neither agent affected a-waves. TPMPA and 2-AEMP increased OP amplitudes starting from -0.8 and -0.5 log sc td s, respectively. Above b-wave saturation, OP amplitudes exhibited a 72±35% increase with TPMPA, and a 150±57% increase with 2-AEMP. In isolated rat bipolar cells, 2-AEMP exhibited GABA antagonist activity that preferentially inhibited GABAc receptors.

Conclusions: : Effects of a newly developed GABAc antagonist 2-AEMP and a known antagonist TPMPA are similar in vivo, causing b-wave attenuation and enhancement of OPs of the dark-adapted mouse ERG.

Keywords: electroretinography: non-clinical • retina: proximal (bipolar, amacrine, and ganglion cells) • neurotransmitters/neurotransmitter systems 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×